Preventing severe graft-versus-host disease after bone marrow transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a guided approach using a special test (daGOAT) combined with a drug called ruxolitinib to prevent severe graft-versus-host disease—a serious complication where transplanted cells attack your body—after a specific type of bone marrow transplant (HLA-haploidentical).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older
- You are receiving or have been approved for an HLA-haploidentical bone marrow or stem cell transplant (a match where the donor shares exactly half of your tissue markers)
- You can swallow and take pills by mouth
- You have not had a bone marrow transplant before, or had multiple transplants
- You are able to take ruxolitinib without severe allergies or side effects
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
Hear when a new Transplant-Related Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.